Getting Started
What Qope IsYour First 15 MinutesInterface TourPlans and Access
Drug Intelligence
Drug ProfilePatent CliffShortages TrackerInsightsTerritory Brief
Access & Organizations
MapSafety-Net IntelligenceEHR Vendor Intelligence
Workspace
Lead ListsRadarPins and Saved Views
Databases
Working with TablesRecord PagesExportsDataset Catalog
Account
Plans and BillingUsage and LimitsTeams and MembersProfile and Security
Data & Methodology
SourcesFreshnessData CaveatsGlossary
Support
FAQTroubleshooting
Open the app
Documentation/Drug Intelligence/Drug Profile

Drug Profile

One page per molecule: approvals, exclusivity, makers, supply, demand, pricing, safety and listings.

Open Drug Profile -- in the sidebar under Drug Intelligence.

Drug Profile is the single most-used page in Qope. It takes one drug name and assembles everything the public registries know about it into one document.

Searching

Type a brand name or an ingredient name into the search box.

  • Lookup uses exact FDA Orange Book and Purple Book names. Type the full brand (Lipitor, Humira) or the full ingredient (atorvastatin calcium).
  • Brand names resolve to the underlying molecule, so searching Lipitor and searching atorvastatin calcium reach the same profile.
  • If nothing matches, Qope offers up to five suggested names rather than an empty page.

Add &vs=<other drug> (or use the compare control) to place two profiles side by side.

The landing dashboard

With no search term, the page shows a landing dashboard: signal carousels of drugs currently worth looking at, drawn from live shortage, cliff and pricing data. It is a starting point, not a saved view.

Header

The hero header carries the primary name, the ingredient, the market-state summary, and the action bar:

  • Watch -- adds the molecule to your Radar drug watchlist.
  • Add to list -- saves it to a lead list.
  • Export -- downloads the profile brief.
  • Compare -- opens the two-drug comparison.

Tabs

Tabs appear only when the underlying data exists for that molecule. A profile with no Medicare Part D presence has no Demand tab.

Overview

The product record: application numbers, approval dates, dosage forms, routes, applicants, marketing status. Below it, the marketed-products card and the contestability meter -- how many generic makers are actively marketing, how many hold approvals that are all discontinued, whether an AB-rated substitutable generic exists, and whether a Reference Listed Drug is on file.

The Verdict

A plain-language read of the drug's market position, scored for three audiences:

PersonaQuestion it answers
Generic entrantIs this worth filing on?
ProcurementIs supply reliable and priced sensibly?
InvestorIs the revenue defensible?

Each verdict shows a rating, a headline, a recommended action, and the full list of factors that moved the score up or down, with the points each contributed. The scoring is a ranking device, not a forecast -- read the factors, not just the number.

Timeline

The regulatory history: original approval, supplements, exclusivity grants and expiries, patent expiries, first generic entry, shortage episodes, recalls. Rendered chronologically so you can see how the market opened.

Makers

Top applicants holding approvals for this ingredient, plus combination products that include it. Applicant names link to filtered Orange Book views.

The Players

Company-level view: who actually markets the drug today versus who merely holds an approval. Includes labeler and manufacturer roll-ups where the source tags a parent company.

Regulatory

Pending applications, original approval, supplement count and last regulatory activity. Present only when there is regulatory movement to show.

Supply

Manufacturing and availability: NDC listings, marketing status, packagers, and any active FDA shortage record with its stated reason and dosage forms.

Demand

Medicare Part D prescribing: top prescribers, claim counts, beneficiary counts and total drug cost. This is prescribing breadth, not spend rank -- a molecule prescribed widely in oral form will show large numbers even if only an injectable presentation is relevant to you.

Pricing

NADAC unit pricing over time, with brand and corresponding-generic prices plotted together. The chart shows the price history for the matched NDC description; the savings percentage compares brand against corresponding generic where both exist.

Safety

FDA adverse event signal and enforcement (recall) history for the molecule, including recall classification and status.

Listings

Every NDC and Orange Book listing tied to the ingredient, for when you need the raw rows.

Caveats worth knowing

  • Combination products frequently resolve to neither a supplier tier nor a demand count. Filtering by a multi-ingredient name would silently match a single component, so Qope shows nothing rather than a wrong number.
  • Biologics follow a different exclusivity regime (12-year BPCIA reference-product exclusivity, tracked in the Purple Book) and do not have ANDA generics. The profile switches its language accordingly.
  • A dormant market -- no marketed generic, protection long lapsed, first approval more than a decade ago -- is flagged separately from a genuine greenfield opportunity.